Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Inclusion Criteria: * Patients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas. Diagnosis from metastatic sampling is acceptable. * Disease must be measured radiologically. * Failed initial therapy or ineligible for definitive curative therapy. * If prior treatment included radiation therapy, recurrent disease must be outside of the targeted volume. * Age ≥ 18 years * ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix A). * Patients must have normal organ and marrow function as defined below: * leukocytes ≥ 3,000/mm3 * absolute neutrophil count ≥ 1,500/mm3 * platelets ≥ 100,000/mm3 * total bilirubin \< 2x institutional upper limit of normal * AST(SGOT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases * ALT (SGPT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases * PT/INR within normal institutional limits, unless patient is on warfarin or other antithrombotic agents * creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Not pregnant. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior chemotherapy to treat metastatic disease. * Adjuvant therapy (including radiation therapy) within 4 calendar weeks. * Unresolved toxicities from prior therapy for the malignancy. * G6PD (glucose-6-phosphate dehydrogenase) deficiency. * Second malignancy other than non-melanoma skin cancers within the past 5 years. * Excess consumption of alcohol where an excess of alcohol is defined as more than four of any one of the following per day: 30 mL distilled spirits, 340 mL beer, or 120 mL wine. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations, or any other condition that would limit compliance with study requirements as determined by study team members. * Pregnant or lactating women: The risks of chemotherapy to a fetus/infant are well documented.